Palliative chemotherapy for patients 70 years of age and older with metastatic colorectal cancer: a single-centre experience.

  title={Palliative chemotherapy for patients 70 years of age and older with metastatic colorectal cancer: a single-centre experience.},
  author={Daniel Bosse and Michael M. Vickers and Fr{\'e}d{\'e}ric Lemay and Annie Beaudoin},
  journal={Current oncology},
  volume={22 5},
BACKGROUND Metastatic colorectal cancer (mcrc) commonly affects elderly people, an understudied subset of patients. We analyzed the survival impact of the first and subsequent lines of chemotherapy in eligible non-trial patients 70 years of age and older with mcrc treated between 2004 and 2012. METHODS This single-centre retrospective analysis estimated overall survival (os) and progression-free survival (pfs) using the Kaplan-Meier method. Multivariate analysis was used to adjust for age… 

Figures and Tables from this paper

Age-dependent differences in first-line chemotherapy in patients with metastatic colorectal cancer: the DISCO study

In the DISCO study, older patients with mCRC received less aggressive first-line chemotherapy, Yet, they experienced more toxicity and hospitalizations.

The effect of geriatric intervention in frail elderly patients receiving chemotherapy for colorectal cancer: a randomized trial (GERICO)

This ongoing trial is one of the first to evaluate the effect of geriatric intervention in frail elderly patients with CRC and will provide new and valuable knowledge about whether it is beneficial for the elderly patient undergoing chemotherapy to be treated simultaneously by a geriatrician.

A Phase II Study of Dose-reductive XELOX Plus Bevacizumab in Elderly or Vulnerable Patients With Metastatic Colorectal Cancer (MCSGO-1202)

The dose-reduction strategy of oxaliplatin was effective for elderly or vulnerable patients with mCRC, and the primary endpoint was the objective response rate.

Bevacizumab (Bmab)+Dihydropyrimidine Dehydrogenase (DPD) Inhibitory Fluoropyrimidine (DIF) Combined Chemotherapy for the Treatment of Late-Stage Elderly Patients with Advanced/Recurent Colorectal Cancer (ARCC)

It is possible to prolong survival through chemotherapy in both late-stage elderly patients and younger patients with ARCC, and Bmab+DIF was suggested to be a candidate treatment for late-Stage elderly patients withARCC.

Real-World Adverse Effects of Capecitabine Toxicity in an Elderly Population

The difference in observed adverse effects cannot be the sole explanation for the high incidence of observed dose adjustments, and a prospective follow-up study of elderly patients using capecitabine outside clinical trials is needed.

Trifluridine/Tipiracil plus Bevacizumab in Patients with Untreated Metastatic Colorectal Cancer Ineligible for Intensive Therapy: the Randomized TASCO1 Study.

First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

TT-B is a promising therapeutic regimen in patients with unresectable metastatic colorectal cancer ineligible for intensive chemotherapy and its results are consistent with prior findings.

Systemic Treatment for Advanced Colorectal cancer : Bridging the gap between clinical studies and daily practice

The studies presented in this thesis focused on the identification of genes that play a central role in the pathogenesis of myelodysplastic syndromes with a deletion of the short arm of chromosome 5, the del(5q) MDS to gain a better understanding of how gene haploinsufficiency in (del)5q MDS leads to a clonal advantage, ineffective hematopoiesis and how haplo INSF can be targeted.



Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies

Benefits were consistent across the studies, irrespective of setting, bevacizumab dose, or chemotherapy regimen, and improvements in PFS and OS benefits in medically fit older patients were consistent.

Chemotherapy compliance, tolerance and efficacy in elderly and non-elderly patients with metastatic colorectal cancer: a single institution comparative study.

Despite the inferior type and intensity of chemotherapy, elderly patients derived equivalent benefit to their younger counterparts, which further support the use of optimal chemotherapy in elderly patients with mCRC.

Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis.

It is concluded that, in patients > or = 70 years of age with advanced CRC, single-agent 5-FU and capecitabine were the favored palliative regimens in British Columbia in 2000 and 2002, respectively.

Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials.

'Fit' elderly patients benefit at least to the same extent from palliative chemotherapy with 5-FU as younger patients and standardized palliatives chemotherapy should generally be offered to elderly patients and they should not be excluded from clinical trials.

Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumab and Chemotherapy: Results from the BRiTE Observational Cohort Study

Elderly patients receiving bevacizumab with first-line chemotherapy showed treatment benefit, although there was reduced median survival with increasing age, and there was no increased toxicity among elderly patients, except for risk of ATEs.

Comparative analysis of second and subsequent chemotherapy lines on short- and long-term survival of elderly Medicare metastatic colon cancer patients.

Elderly (65+) SEER-Medicare patients diagnosed with mCC in 2003-2007 were followed until death or 12/31/09 to examine the survival benefits for different chemotherapy lines.

Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C.

Addition of B to C significantly improved PFS in this geriatric population, with similar benefits to those aged <75 years, with no impact of age.

Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.

Patients older than 70 years of age who were selected for inclusion in phase III trials derived similar benefits as younger patients from irinotecan-containing chemotherapy, and the risk of toxicity was similar.

Toxicity of bevacizumab in combination with chemotherapy in older patients.

Older patients who receive bevacizumab with chemotherapy have a higher odds of developing a grade 3-5 toxicity compared with those who receive chemotherapy alone.

How does older age influence oncologists' cancer management?

Advanced age can deter oncologists from choosing intensive cancer therapy, even if patients are highly functional and lack comorbidities, and education on tailoring cancer treatment and a greater use of comprehensive geriatric assessment may reduce cancer undertreatment in the geriatric population.